Opinion

Video

Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice

Cara Chang, PharmD, BCOP, provides a comprehensive analysis of the MARIPOSA-2 trial, evaluating the various study arms and interpreting the practice-changing data presented.

  1. The MARIPOSA-2 trial, a recent publication from January, assessed patients with Ex19del or Ex21 L858R mutations who had progressed on osimertinib. It compared three treatment arms: amivantamab plus lazertinib plus chemotherapy, amivantamab plus chemotherapy (without lazertinib), and chemotherapy alone. What are the significant findings of this study, and what are the key insights that could influence clinical practice?
  2. When it comes to patients with S768I, L861Q, and/or G719X mutations, how does their treatment approach differ from (or is similar to) those observed in the FLAURA2 and MARIPOSA / MARIPOSA-2 studies?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
5 experts in this video
1 expert is featured in this series.
5 experts in this video
5 experts in this video
1 expert is featured in this series.
Related Content
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
June 30th 2025

ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC

Christopher Danes, PhD Alana Hippensteele, Lead Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

3D rendering of lung cancer screening x-ray | Image Credit: © Vector Market- stock.adobe.com
Published: June 23rd 2025 | Updated: June 23rd 2025

FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
June 27th 2024

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

OPC 2025: Advancing Precision Oncology Through Pharmacy-Led Innovation
June 19th 2025

OPC 2025: Advancing Precision Oncology Through Pharmacy-Led Innovation

Alana Hippensteele, Lead Editor
Visualization of human lungs with cancer | Image Credit: © iDoPixBox - stock.adobe.com
June 19th 2025

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Alexandra Gerlach, Associate Editor